Data Presented at SABCS 2025 Demonstrated that the Endocrine Activity Index® (EAI®) May Identify Patients Most Likely to Benefit from Extended Endocrine Therapy
PR Newswire —
HOUSTON, Feb. 16, 2026 /PRNewswire/ -- New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP B-42 trial demonstrated that the Endocrine Activity Index (EAI) identifies postmenopausal women with hormone receptor–positive (HR+), HER2-negative breast...